WO1996022304A1 - Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes - Google Patents

Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes Download PDF

Info

Publication number
WO1996022304A1
WO1996022304A1 PCT/US1996/000786 US9600786W WO9622304A1 WO 1996022304 A1 WO1996022304 A1 WO 1996022304A1 US 9600786 W US9600786 W US 9600786W WO 9622304 A1 WO9622304 A1 WO 9622304A1
Authority
WO
WIPO (PCT)
Prior art keywords
turn
amino acid
library
mimetic
mimetics
Prior art date
Application number
PCT/US1996/000786
Other languages
English (en)
Inventor
Michael Kahn
Original Assignee
Molecumetics, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecumetics, Ltd. filed Critical Molecumetics, Ltd.
Priority to JP8522413A priority Critical patent/JPH10512570A/ja
Priority to AU47619/96A priority patent/AU4761996A/en
Priority to EP96903585A priority patent/EP0804460A1/fr
Publication of WO1996022304A1 publication Critical patent/WO1996022304A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Definitions

  • This invention relates generally to libraries of conformationally constrained reverse-turn mimetics, methods relating to the identification of library members that interact with biological targets of interest, and the use of such members as diagnostic, prophylactic and/or therapeutic agents.
  • Random screening of molecules for possible activity as therapeutic agents has occurred for many years and resulted in a number of important drug discoveries. While advances in molecular biology and computational chemistry have led to increased interest in what has been termed "rational drug design", such techniques have not proven as fast or reliable as initially predicted. Thus, in recent years there has been a renewed interest and return to random drug screening. To this end, particular strides having been made in new technologies based on the development of combinatorial chemistry libraries, and the screening of such libraries in search for biologically active members.
  • combinatorial chemistry libraries are simply a collection of molecules. Such libraries vary by the chemical species within the library, as well as the methods employed to both generate the library members and identi y which members interact with biological targets of interest. While this field is still young, methods for generating and screening libraries have already become quite diverse and sophisticated. For example, a recent review of various combinatorial chemical libraries has identified a number of such techniques, including the use of both tagged and untagged library members (Janda, Proc. Natl. Acad Sci. USA 91:10779-10785, 1994). To date, combinatorial chemistry libraries have generally been limited to members of peptide or nucleotide origin. To this end, the techniques of Houghten et al.
  • N-acylated peptide library has been used to identify acetalins, which are potent opioid antagonists (Dooley et al., Proc. Nail Acad Sci. USA 90:10811-10815, 1993). More recently, an all D-amino acid opioid peptide library has been constructed and screened for analgesic activity against the mu (" ⁇ ") opioid receptor (Dooley et al, Science 266:2019-2022, 1994).
  • the present invention is directed to libraries of conformationally constrained reverse-turn mimetics and methods relating to the generation thereof.
  • This invention is further directed to methods relating to the screening and identification of library members that interact with biological targets of interest, as well as the use of such identified members as diagnostic, prophylactic and/or therapeutic agents.
  • a library containing a plurality of conformationally-constrained reverse-turn mimetics as members is disclosed, the structures of which are set forth in greater detail in the following detailed description.
  • a method for identifying biologically active agents comprising screening the above library members in a suitable assay, and thereby identifying biologically active library members.
  • a method for identifying a biologically active conformationally constrained reverse-turn mimetic which mimics a biologically active conformation of a linear peptide having a known amino acid sequence.
  • conformationally constrained reverse-turn mimetics are constructed based on the known amino acid sequence of the linear peptide to yield a template library containing a plurality of members selected from conformationally constrained beta-turn, gamma-turn and beta-bulge mimetics having multiple ring sizes.
  • the template library members are then screened in a suitable assay to identify a biologically active member of the template library.
  • conformationally constrained reverse-turn mimetics are constructed based on the biologically active member of the template library to yield an optimized library containing a plurality of members having varying amino acid substitutions based on the known amino acid sequence of the biologically active linear peptide.
  • the optimized library members are screened in a suitable assay to identify a biologically active member of the optimized library.
  • conformationally constrained reverse-turn mimetics are disclosed which are useful as diagnostic, prophylactic and/or therapeutic agents.
  • the structure of such mimetics, as well as methods to synthesis the same, are disclosed in greater detail in the following detailed description.
  • Figures 1A-1B illustrate a representative synthesis of conformationally constrained beta-turn mimetics having 12- and 14-membered rings.
  • Figures 2A-2C illustrate a representative synthesis of a conformationally constrained beta-turn mimetic having a 10-membered ring, as well as a gamma-turn mimetic having a 7-membered ring.
  • the present invention is generally directed to libraries containing conformationally constrained reverse-turn mimetics of naturally occurring or synthetic peptides (referred to herein as “reverse-turn mimetics” or “mimetics”), and which are useful in the identification of bioactive agents, such as diagnostic, prophylactic and/or therapeutic agents.
  • the libraries may contain from tens to hundreds to even millions of individual reverse-turn mimetics (also referred to herein as "members").
  • the libraries of the present invention may be screened to identify individual members having bioactivity. Such screening of the libraries for bioactive members may involve, for example, evaluating the binding activity of the members of the library or evaluating the effect the library members have on a functional assay.
  • Screening is normally accomplished by contacting the library members (or a subset of library members) with a target of interest, such as, for example, an antibody, enzyme, receptor or cell line.
  • a target of interest such as, for example, an antibody, enzyme, receptor or cell line.
  • Library members which are capable of interacting with the target of interest are referred to herein as "bioactive library members” or “bioactive mimetics”.
  • a bioactive mimetic may be a library member which is capable of binding to an antibody or receptor, which is capable of inhibiting an enzyme, or which is capable of eliciting or antagonizing a functional response associated, for example, a cell line.
  • the screening of the libraries of the present invention determines which library members are capable of interacting with one or more biological targets of interest.
  • bioactive mimetic may then be identified from the library members.
  • the identification of a single (or limited number) of bioactive mimetic(s) from the library yields reverse-turn mimetics which are themselves biologically active, and thus useful as diagnostic, prophylactic or therapeutic agents, and may further be used to significantly advance identification of lead compounds in these fields.
  • the steps which are undertaken to identify a bioactive mimetic from the library depends primarily on whether the library is spatially or nonspatially addressable. While either library type is permitted in the practice of this invention, spatially addressable libraries are preferred. In a spatially addressable library, each reaction vessel in which an assay is performed contains a single mimetic or a small number of mimetics.
  • a bioactive mimetic when identified in a screening assay, its identity is specifically known, or known to be of a limited number of mimetics.
  • the size of spatially addressable libraries are limited by the required degree of spatial resolution.
  • significant advances have recently been made which permit a relatively large number of members within a spatially addressable library.
  • photolithographic techniques now allow for the spatial resolution of relatively large number of members (on the order of 64,000) in a small area, such as a 1.5 cm 2 chip. (Fodor et al., Science 251:717-723, 1991; Cho et al., Science 261: 1303- 1305, 1993) (both of which are incorporated by reference herein).
  • nonspatially addressable libraries can be made by constructing an encoded library as disclosed by Ohlemeyer et al. ⁇ Proc. Nail. Acad Sci. USA 90:10922-10926, 1993) and Brenner et al. ⁇ Proc. Natl. Acad Sci. USA 89:5181- 5183, 1992) (both of which are incorporated herein by reference).
  • a nonspatially addressable library requires the ability to directly sequence the minute quantity of product that is associated with a polymer bead in the synthesis. This is readily achievable at the 5-10 picomolar range with peptide sequencing.
  • a nonsequenceable number can be cosynthesized with a coding sequenceable partner (e.g., peptide or oligonucleotide) which can be directly sequenced, or PCRed and sequenced.
  • a coding sequenceable partner e.g., peptide or oligonucleotide
  • Small sequenceable coding strands can be made which can be sequenced using mass spectroscopy ⁇ see, e.g., Ohlemeyer et al., Nikolaiev et al., Peptide Res. 6:161-170, 1993) (incorporated herein by reference).
  • mass spectroscopy see, e.g., Ohlemeyer et al., Nikolaiev et al., Peptide Res. 6:161-170, 1993
  • the mimetics of the present invention comprise conformationally constrained reverse-turn mimetics and, more specifically, encompass compounds of related structures, including mimetics of beta-turns ( ⁇ -turns), gamma turns ( ⁇ -turns), and beta-bulges ( ⁇ -bulges).
  • beta-turns are reversals in the direction of a polypeptide chain wherein the oxygen of the CO group of amino acid n is hydrogen bonded to the hydrogen of the NH group of amino acid n+3.
  • gamma-turns and beta-bulges are reversals in a polypeptide chain where the oxygen of the CO group of amino acid n is hydrogen bonded to the hydrogen of the NH group of amino acid n+2 and n+4, respectively.
  • conformationally constrained reverse-turns of this invention "mimic" the three-dimensional structure of beta-turns, gamma-turns and beta-bulges, and thus serve as surrogates for such reverse-turn structures present in naturally-occurring proteins and/or peptides.
  • a conformationally constrained beta-turn mimetic of this invention has the following structure I or II:
  • Rl, R 2 , R3 and R 4 are amino acid side chain moieties or derivatives thereof
  • X is selected from the chemical moieties identified in Table 1
  • Y is selected from -CH2., -N(Z)-, -O- and -S-, and Z is -H or -CH3.
  • a conformationally constrained gamma-turn mimetic of this invention has the following structure m or IN:
  • R*, R 2 and R 4 are amino acid side chain moieties or derivatives thereof
  • X is selected from the chemical moieties identified in Table 1
  • Y is selected from -CH2-, - ⁇ (Z)- , -O- and -S-, and Z is -H or -CH3.
  • a conformationally constrained beta-bulge mimetic of this invention has the following structure V or VI:
  • R*, R 2 , R 3 , R 3 and R 4 are amino acid side chain moieties or derivatives thereof
  • X is selected from the chemical moieties identified in Table 1
  • Y is selected from -CH 2 -, -N(Z)-, -O-, and -S-, and Z is -H or -CH 3 .
  • ⁇ R indicates that the amino acid side chain moiety (or derivative thereof) may lie either above or below the plane of the page.
  • the R amino acid side chain moieties would lie below the plane of the page in structures I through VI above (i.e., " R").
  • the corresponding R amino acid side chain moiety would lie above the plane of the page in the above structures (i.e., " — ⁇ R”).
  • L-amino acids are employed to more closely mimic the structure of native protein.
  • an amino acid side chain moiety represents any amino acid side chain moiety present in naturally occurring proteins, including (but not limited to) the naturally occurring amino acid side chain moieties identified in Table 2.
  • Other naturally occurring amino acid side chain moieties of this invention include (but are not limited to) the side chain moieties of 3,5-dibromotyrosine, 3,5-diiodotyrosine, hydroxylysine, ⁇ -carboxyglutamate, phosphotyrosine and phosphoserine.
  • glycosylated amino acid side chains may also be used in the practice of this invention, including (but not limited to) glycosylated threonine, serine and asparagine.
  • the five-membered pyrrolidine ring may be a component of the conformationally constrained reverse-turn mimetic.
  • proline may be present at any location within the conformationally constrained reverse-tum mimetic in place of one or more M -NH-CH(R)-" moieties.
  • inclusion of proline in structures I through VI above at the M -Y-CH(R 2 )-" position yields the following structures 1(a) through VI(a):
  • R 1 , R 3 , R 3 ', R 4 , X and Z are as identified above with regard to structures I through VI.
  • structures I and II may be modified by inclusion of proline within the conformationally constrained reverse-turn mimetic at the M -NH-CH(R 3 )-" position, yielding structures 1(b) and 11(b) below:
  • structures V and VI may be modified by inclusion of proline within the conformationally constrained reverse-turn mimetic at the "-NH-CH(R 3 )- M or H -NH-CH(R 3 ')-" positions, yielding structures V(b), VI(b), V(c) and VI(c):
  • R , R 2 , R 3 , R 3 ', R 4 > X, Y and Z are as identified above with regard to structures I through VI.
  • general structures I through VI above include structures 1(a), ⁇ (a), m(a), IV(a), V(a), VI(a), 1(b), 11(b), V(b), VI(b), V(c) and VI(c) as representative examples where the amino acid side chain moiety is proline (or a derivative thereof).
  • conformationally constrained reverse-turn mimetics of the present invention are made by utilizing appropriate starting component molecules (hereinafter referred to as "component pieces").
  • component pieces appropriate starting component molecules
  • first, second and third component pieces are combined (in various combinations) and then cyclized to yield the conformationally constrained reverse-turn mimetics of this invention
  • a "first component piece” has the following structure I:
  • R 4 is an amino acid side chain moiety or derivative thereof
  • X is selected from the chemical moieties identified in Table 1
  • P is a protective group suitable for use in peptide synthesis.
  • a "second component piece” of this invention is selected from the following structures 2(a), 2(b) and 2(cV
  • R 3 is an amino acid side chain moiety or derivative thereof
  • W is -H, -OH alkyl, aryl, -O-alkyl, -O-aryl, -S-alkyl or -S-aryl
  • P is a protective group suitable for use in peptide synthesis.
  • a "third component piece” of this invention is selected from the following structures 3£a 3 ⁇ b) and 3(cV.
  • R* and R 2 are amino acid side chain moieties or derivatives thereof
  • Y is -CH2-, -NZ-, -O- or -S-
  • Z is H or methyl
  • W is -H, -OH, alkyl, aryl, -O-alkyl, -O-aryl, -S-alkyl, or -S-aryl
  • P is a protective group suitable for use in peptide synthesis.
  • conformationally constrained beta-turn mimetics of this invention are synthesized by reacting a first component piece with a second component piece to yield a combined first-second intermediate, followed by reacting the first-second intermediate with a third component piece to yield a combined first-second-third intermediate, and then cyclizing the resulting first-second- third intermediate to yield the conformationally constrained beta-turn mimetic.
  • Conformationally constrained gamma-turn mimetics ⁇ see structures III and IV above are synthesized in the same manner, except that the second component piece is omitted (i.e., a first-third intermediate is cyclized).
  • conformationally constrained beta- bulges are synthesized by use of two second component pieces (i.e., a first-second-second-third intermediate is cyclized).
  • first modular component piece 1 is combined with a second modular component piece 2(a) to yield a first-second intermediate 5 as illustrated below (it should be recognized that following reaction scheme is presented for illustration purposes, and that the carboxylic acid moiety of structure I should be suitably protected by, for example, esterification, by formation of an amide bond, or by attachment to a solid support):
  • a third modular component piece 3fal) is then combined with the first-second intermediate 5 to give a pre-cyclized beta-turn mimetic 6, which in turn is cyclized to yield the beta-turn mimetic of structure 4:
  • All conformationally constrained reverse-turn mimetics of this invention may be synthesized by appropriate choice of the various component pieces by the general procedure outlined above.
  • R group variations to structures I through VI may be made by use of appropriate first, second and third component piece possessing the desired R group.
  • conformationally constrained gamma-tur mimetics may be synthesized by linking a first component piece with a third componen piece (omitting the second component piece), followed by cyclization.
  • first component piece may be combined with a second component piece, followed b combination with yet another second component piece to yield a first-second-secon intermediate.
  • This intermediate may then be combined with a third component piece an cyclized to yield the corresponding conformationally constrained beta-bulge mimetic. Additional disclosure directed to the synthesis of the conformationally constraine reverse-turn mimetics of this invention is set forth in Examples 1-3 below.
  • Synthesis of the peptide mimetics of the library of the present inventio may be accomplished using known peptide synthesis techniques, in combination with th first, second and third component pieces of this invention. More specifically, any amino acid sequence may be added to the N-terminal and/or C-terminal of the conformationall constrained reverse-turn mimetic. To this end, the mimetics may be synthesized on a solid support (such as PAM resin) by known techniques ⁇ see, e.g., John M. Stewart and Janis D. Young, Solid Phase Peptide Synthesis, 1984, Pierce Chemical Comp., Rockford, Illinois).
  • a combination of both solution and solid phase synthesis techniques may be utilized to synthesize the peptide mimetics of this invention.
  • a solid support may be utilized to synthesize the linear peptide sequence up to the point that the conformationally constrained reverse-turn is added to the sequence.
  • a suitable conformationally constrained reverse-turn mimetic which has been previously synthesized by solution synthesis techniques may then be added as the next "amino acid" to the solid phase synthesis (i.e., the conformationally constrained reverse-turn mimetic, which has both an N-terminus and a C-terminus, may be utilized as the next amino acid to be added to the linear peptide).
  • the conformationally constrained reverse-turn mimetic Upon incorporation of the conformationally constrained reverse-turn mimetic into the sequence, additional amino acids may then be added to complete the peptide vaccine bound to the solid support.
  • the linear N-terminus and C-terminus protected peptide sequences may be synthesized on a solid support, removed from the support, and then coupled to the conformationally constrained reverse-turn mimetic in solution using known solution coupling techniques.
  • the peptide library described above results in a traditional combinatorial library derived from naturally occurring amino acids.
  • Traditional combinatorial libraries consist of members differing only in the sequence in which its constituents are combined.
  • a library of octapeptides consists of members including ABCDEFGH, ACBDEFGH, ABDCEFGH, etc., where A-H represent amino acids.
  • the library is composed of conformationally constrained reverse- turn mimetics. That is, for any given peptide sequence, a multitude of reverse-turns are possible.
  • the libraries of the present invention may be significantly larger and more diverse than a library constructed solely by sequence variation of a linear peptide.
  • Such reverse-turn mimetic libraries provide not only compounds of fixed sequence, but within each fixed sequence, provide a family of mimetics of various fixed conformations.
  • the above library generally comprises 5 beta-turn mimetics, 6 gamma-turn mimetics and 4 beta-bulge mimetics. Moreover, for each one of the above representations, additional reverse-turn mimetics may be constructed. As disclosed above, the conformation of the reverse-turn mimetics are constrained by cyclizing the first and third component pieces through covalent coupling of linking group X of the first component piece with the carbonyl of the azetidinone group of the third component piece ⁇ see Example 3).
  • first and third component pieces determines the nature of the reverse-turn mimetic: cyclization of first-second-third, first- third, and first-second-second-third component pieces yield beta-turn, gamma-turn, and beta-bulge mimetics, respectively. Accordingly, in addition to the multiplicity of reverse- turns possible for a given sequence, variation of linking group X ⁇ see Table 1) provides even greater diversity of the mimetic library.
  • the libraries of the present invention thus differ from existing combinatorial libraries of linear peptides.
  • the reverse-turn library is necessarily larger because of the number of possible linker groups X and, therefore, there is a smaller amount of any one component in the library, thus making any single component harder to find (Medynski, Biotechnology 12:709-710, 1994).
  • Linear peptide libraries can be sequenced using peptide microsequencing techniques, which can provide sequence information on as little as picomolar levels of material ⁇ see, e.g., Lam et al., Nature 354:82-84, 1991).
  • Lam et al. Nature 354:82-84, 1991.
  • one must be able to cleave the individual amino acids in the peptide.
  • the reverse turn mimetics of this invention do not have this capability within the conformationally constrained ring, which thus precludes this type of sequencing.
  • the libraries are based on a known linear peptide sequence as the starting point.
  • the peptide sequence may be derived from a naturally occurring peptide or protein, or may be generated via a biopolymer library such as a synthetic peptide or phage display.
  • the libraries of the present invention are preferably constructed in two phases: (1) determination of the best template, and (2) optimization of the interaction of the side chains of the selected template. Both of these phases involve evaluation of the interaction of the individual library members with a particular biological target of interest as discussed below.
  • the determination of the best template entails evaluation of various possible reverse-turns for the particular sequence chosen.
  • the first phase searches out the shape of the mimetic for presentation of the sequence information.
  • a library of the type shown below is first constructed.
  • the above represents a nested set of beta-turn, gamma-turn, and beta-bulge turn mimetics of different sizes and conformations based on the primary sequence ABCDEF.
  • the above library consists of three beta-turns, with each turn containing a different linker group X. For example, if three different linker groups are used, beta-turn mimetics containing 10-, 12-, and 14-membered rings may be prepared ⁇ see Example 3). Similarly, the above library also consists of four gamma-turn mimetics, and by appropriate selection of X, gamma-turn mimetics containing 7-, 9-, and 11-membered rings may be prepared.
  • the above library further consists of two beta-bulge mimetics which, using three different X linker groups, results in beta-bulge mimetics containing 13-, 15-, and 17-membered rings.
  • the selection of the best template is performed by contacting the library members with the target of interest in a suitable assay.
  • the best template (as determined by the positive interactions or "hits" of the assay) may be a beta-turn containing a 12-membered ring such as shown below.
  • the side chains of the template are then optimized.
  • the template is maintained and the various residues (A through F) are randomized.
  • the randomization involves the synthesis of additional compounds in which other side chains (other amino acid derived component pieces) are substituted. Both turn residues (C-F) and adjacent residues (A- B) may be randomized.
  • the randomization may be carried out in a single screen, or alternatively, the randomization may be separated into two or more rounds of screening.
  • the determination of the optimal side chains is achieved by screening using an appropriate assay.
  • the results of the screening assay may provide a beta-turn containing a 12-membered ring with a sequence as shown below. 12
  • the libraries of the present invention may be screened for bioactivity by a variety of techniques and methods.
  • the screening assay may be performed by (1) contacting a library with a biological target of interest, such as a receptor, and allowing binding to occur between the mimetics of the library and the target, and (2) detecting the binding event by an appropriate assay, such as by the colorimetric assay disclosed by Lam et al. ⁇ Nature 354:82-84, 1991) or Griminski et al. ⁇ Biotechnology, 12:1008-1011, 1994) (both of which are incorporated herein by reference).
  • the library members are in solution and the target is immobilized on a solid phase.
  • the library may be immobilized on a solid phase and may be probed by contacting it with the target in solution.
  • the structure of the bioactive mimetic will be known, or known to be of a limited number of structures.
  • certain characteristics and properties may be imposed upon the reverse-turn mimetic to facilitate the recognition of bioactivity in a screening assay and also to permit the isolation and identification of the mimetic.
  • a receptor- bound bioactive mimetic may be collected through a binding interaction with a solid phase immobilized ligand-binding protein, such as avidin immobilized on a magnetic bead.
  • the mimetic need possess a suitable ligand.
  • the immobilized ligand binding protein is avidin
  • the mimetic ligand is preferably biotin.
  • the bioactive mimetic may be readily removed from the immobilized receptor by applying a magnetic field. For example, contacting the magnetic beads with a magnet is effective in separating the mimetic from the receptor. To identify the bioactive mimetic, the mimetic is then released from the magnetic solid phase by, for example, cleavage. Cleavage of the mimetic from the magnetic bead may occur through either chemical or enzymatic means. In either case, the mimetic should possess a suitable cleavable linkage.
  • the mimetic is cleaved from the magnetic bead by enzymatic means and the cleavable linkage is a peptide sequence susceptible to enzymatic cleavage.
  • the enzyme thrombin effectively cleaves the sequence GRG (glycine-arginine-glycine). Accordingly, thrombin treatment of a magnetically bead bound mimetic possessing a cleavable link GRG results in cleavage of the GRG sequence and release of the bioactive mimetic. Additional strategies for cleavable linkers are disclosed by Patek et al., Int. J. Peptide Protein Res. 42:97-117, 1993 (incorporated herein by reference).
  • the conformationally-constrained reverse-turn mimetics of the present invention may thus incorporate a cleavable linker to facilitate release of a bioactive mimetic from the mimetic screening format prior to mimetic identification.
  • Preferred linkers are amino acid sequences capable or prone to proteolytic breakdown.
  • the cleavable linker of this invention is preferably located between the conformationally constrained reverse-turn mimetic and the ligand (such as biotin or the trypsin-like serine protease Factor X).
  • a further cleavable linker of this invention contains a recognition site (i.e., cleavage site) for the aspartic protease cathepsin D.
  • Other cleavable linkers of this invention include, but are not limited to, the amino acid sequences which are cleavable by cathepsin B or by cathepsin E.
  • Cathepsin B is a cystein proteinase which cleaves sequences having a basic amino acid (such as arginine or lysine) at the P 2 and P positions, a small hydrophobic moiety at Pj, and an aromatic hydrophobic moiety at P j ' and P4 ⁇ see Matsueda et al., The Chemical Society of Japan - Chemistry Letters pp. 1857-1860, 1988; Matsunaga et al., FEBS 324:325-330, 1993).
  • cathepsin E is an endosomal aspartic proteinase present in both B and T cells, but not in peritoneal macrophages.
  • the active clefl of this enzyme is capable of accommodating as many as nine residues, with a distinct preference for cleavage to occur between hydrophobic residues occupying the Pi-P]' sites ⁇ e.g, Bennett et al., Eur. J. Immunol. 22:1519-1524, 1992).
  • the mimetic includes both a ligand (such as biotin for effective collection from the receptor), and a cleavable linkage (such as a peptide sequence susceptible to enzymatic cleavage).
  • a ligand such as biotin for effective collection from the receptor
  • a cleavable linkage such as a peptide sequence susceptible to enzymatic cleavage.
  • Such mimetics may be prepared by traditional chemistries that are complementary to and may be directly incorporated into the solid or liquid phase synthesis of the mimetics described above. To that end, the incorporation of biotin and cleavable linkages are preferably made on the C terminus of the mimetic.
  • the mimetic may be schematically represented by the following representation: N-terminus - reverse-turn mimetic - C terminus - cleavable link - ligand
  • the above mimetics may be synthesized by the same methods which yield the reverse-turn mimetics themselves. Briefly, in order to incorporate a ligand such as biotin into the mimetic, a lysine residue is incorporated into the mimetic as the first residue.
  • the nucleophilic epsilon amino group of the lysine side chain serves as the reactive site for the coupling of a ligand such as biotin.
  • a reactive form of biotin such as the N-hydroxysuccinimde of biotin results in coupling of biotin to the mimetic.
  • the peptide mimetic synthesis may then be continued by the addition amino acid residues suitable to make up the cleavage site.
  • the residue glycine, arginine, and glycine may be coupled to provide such a cleavable link.
  • peptide mimetic synthesis follows as described above and in Examples 1-3.
  • methods for the identification of bioactive mimetics are disclosed.
  • the bioactive mimetic may be released by treatment with a suitable enzyme. The result is a solution containing individual bioactive mimetics and the cleaving enzyme.
  • the bioactive mimetics may be separated from the cleaving enzyme by traditional techniques such as size exclusion filtration to provide a solution of bioactive mimetics suitable for analysis.
  • the solution of bioactive mimetics is analyzed by the combination of liquid chromatography and mass spectrometry (LC-MS).
  • LC-MS liquid chromatography and mass spectrometry
  • liquid chromatographic analysis provides both a means for separation and quantification of the bioactive mimetics.
  • the chromatogram of such a mixture provides a binding profile of the mimetics.
  • Elution of the liquid chromatogram into the mass spectrometer provides unambiguous identification of the bioactive mimetics.
  • the first component piece of this invention has the following structure _
  • R 4 is an amino acid side chain moiety or derivative thereof
  • X is a chemical moiety selected from the moieties identified in Table 1
  • P is an amino protective group suitable for use in peptide synthesis.
  • the "X" moiety establishes the bridge between the first and third component pieces which defines the ring size of the conformationally constrained reverse-turn mimetic.
  • the X moiety may be variable in length and flexibility, and thus effects the three-dimensional structure of the conformationally constrained reverse-turn mimetic.
  • the first component piece may be an N-protected hydrazine where the moiety X is a single nitrogen atom. Upon cyclization to the reverse turn mimetic, such a first component piece forms a hydrazide link with the carbonyl group of the third component piece. Alternatively, the first component piece may be an N-protected amine which upon cyclization forms an amide link.
  • the synthesis of both general types of first compound pieces is set forth below.
  • the ⁇ -hydroxy group is displaced with mono-t-butyloxycarbonyl hydrazine after its conversion to trifluoromethanesulfonate with trifiuoromethanesulfonic anhydride (with overall inversion of the amino acid configuration about the chiral carbon atom).
  • the result is a first component N-protected hydrazine, a first component piece represented by formula I where the carboxylic acid group is protected as a methyl ester, X is NH, and P is the amino protective group, t-butyloxycarbonyl (BOC).
  • the conversion of an amin acid to a representative first component N-protected hydrazine is shown below.
  • first component pieces may be prepared from suitable aldehydes by a facile reductive amination process, as described by Gribble and Nutatitis ⁇ Org. Prep. Proced Int. 17:317, 1985) or Sasaki and Coy ⁇ Peptides 8: 119, 1987).
  • reaction of the amino group of an amino acid with the carbonyl group of an aldehyde results in the formation of an imine which may be subsequently reduced with an appropriate hydride reducing agent to provide a C-N link.
  • the requisite aldehyde bears a N- protected amino group.
  • the synthesis of first component N-protected amines by general method of reductive amination is presented schematically below (with overall retention of the amino acid configuration about the chiral carbon atom):
  • synthesis of the above N-protected amines may be accomplished on solid support by substituting the HOOC-CH(R )-NH2 moiety with P* OOC-CH(R 4 )-NH 2 to yield P-OOC-CH(R 4 )-NHCH 2 RNHP.
  • P is an amino protecting group
  • the product of the reductive amination shown above yields the first component piece of structure I when X is NH-R-CH2.
  • aldehydes from amino acids.
  • the preparation of first component pieces with variable X by the reductive amination method requires the synthesis of suitable aldehydes, i.e., aldehydes which bear N-protected amino groups.
  • suitable aldehydes may be directly prepared from their corresponding amino acids by a two step procedure as described by Goel et al. ⁇ Org. Syn. 67:69, 1988).
  • an N-protected amino acid is first converted to a mixed anhydride by treatment with methyl chloroformate and treatment with N,O-dimethylhydroxylamine provides the corresponding carboxamide, which is followed by reduction to the aldehyde with lithium aluminum hydride.
  • the conversion of an N-protected amino acid to its corresponding N-protected aldehyde, as described above, is illustrated schematically b the following reaction:
  • the aldehyde is an N-protected 2-aminoethanol and may be prepared from its corresponding N-protected amino acid, glycine, according to the process of Goel et al. as described in section (2) above.
  • N-BOC-glycine is commercially available from a variety of sources and is suitable for conversion to its aldehyde, BOC- NH-CH2-CHO.
  • the aldehyde is an N-protected 2-amino-2-methylpropanal, and may be prepared from its corresponding N-protected amino acid, 2-methylalanine, according to the process of Goel et al. as described in section (2) above.
  • N-BOC-2- methylalanine is commercially available from a variety of sources and is suitable for conversion to its aldehyde, BOC-NH-C(CH 3 )2-CHO.
  • ester product above may then be hydrolyzed under basic conditions to yield the corresponding N-BOC amino carboxylic acid, which may then be directly converted to the aldehyde by the reductive method of Goel et al. as described above in section (2). Conversion of the carboxylic acid derived from the above ester to the corresponding aldehyde is illustrated below.
  • the second component pieces of this invention may have any one of the following structures 2a, 2b or 2c:
  • R 3 is an amino acid side chain moiety or derivative thereof
  • W is as defined previously
  • P is an amino protective group suitable for use in peptide synthesis.
  • Structure 2a is a generalized representation of an N-protected amino acid and structure 2b represents an N-protected proline derivative.
  • Suitable second component pieces, 2a and 2b, are commercially available.
  • FMOC amino acids are available from a variety of sources.
  • these or other N-protected amino acids may be readily prepared by standard organic synthetic techniques.
  • Second component piece 2c. is an azido derivative of an amino acid.
  • the ⁇ -amino group has been substituted with an azido group.
  • the azido derivative of an amino acid may be prepared by the following reaction (Zaloom et al., J. Org. Chem. 46:5173-5176, 1981):
  • the third component piece may have any one of the following structures:
  • Rl and R 2 are an amino acid side chain moieties or derivatives thereof, Y is
  • -CH2_, -NZ-, -O- or -S-, Z is H or -CH 3
  • W is as defined previously
  • P is an amino protective group suitable for use in peptide synthesis.
  • Preferred protective groups include t-butyl dimethylsilyl (TBDMS), BOC, FMOC and Alloc (i.e., allyloxycarbonyl).
  • third component piece 3(a) may have any one of the following structures:
  • the third component pieces of the present invention are ⁇ -propiolacta derivatives, also commonly known as 2-azetidinone derivatives.
  • Third component piec _ are analogous azetidinones which differ in the nature of the atom connecting t azetidinone ring with the carboxylic acid portion of the molecule. The atom connectin the two portions of these third component pieces are C, N, O and S for 3(al). 3(a2 3(a3) and 3(a4). respectively.
  • Third component piece 3b is a derivative of 3a(2 wherein R 2 is proline.
  • Third component piece 3c is a 2-substituted azetidinone in whic the azetidinone nitrogen is also the ⁇ -amino group of an ⁇ -amino acid. Representati syntheses of these third component pieces 3a-3c follows.
  • Third component piece 3(al) may be prepared by the method as generall described in Williams et al., J. Amer. Chem. Soc. 111:1073, 1989. The synthesis 3(al) is presented schematically below.
  • N-TBDMS-2-azetidinone generated by treatment with lithiu dusopropylamide is alkylated with a 4-bromobutenyl derivative to yield th corresponding 4-butenyl azetidinone.
  • Oxidative cleavage of the terminal alkene wit ruthenium tetroxide provides third component piece 3(al). where P is the TBDM protective group.
  • Third component piece 3(a2) may be prepared by the method as generally described in Miller et al. ⁇ J. Amer. Chem. Soc. 102:7026, 1980). The synthesis of 3 ( a2 ) is presented schematically below.
  • Third component piece 3(a3) may be prepared by the method as represented schematically below:
  • the third component piece 3(a3) i prepared by the following procedure:
  • Third modular component piece 3(a4) is made in the same manner as 3(a3). except POC(O)CH(R 2 )S" is added in place of the allyl alcohol, and the resulting ester is hydrolysed to yield 3(a4).
  • Third modular component piece 3b is made in the same manner as 3(a3). except an ester of proline is added in place of the allyl alcohol, and the resulting ester is hydrolysed to yield 3(b).
  • (6) Synthesis of Third Component Piece 3 c Third component piece 3c may be prepared by the method as generally described in Hart and Hu ⁇ Chem. Rev. 89:1447, 1990). The synthesis of 3c. is presented schematically below.
  • third component piece 3c where Z is hydrogen.
  • Example 2 The Coupling of First. Second and/or Third Component Pieces
  • the coupling of the component pieces to produce the reverse-turn mimetics of the present invention generally involve the formation of amide bonds.
  • the amide bonds which link the pieces may be formed by standard synthetic peptide techniques and may be performed by either liquid or solid phase synthesis.
  • the first component piece is incorporated into the peptide sequence at a specific point in the synthesis. Once the first component piece is incorporated, the synthesis of the remainder of the mimetic turn follows.
  • the turn is synthesized by subsequent coupling of a second and a third component piece, followed by cyclization o the first component piece to the third component piece.
  • the remainder of the peptide may then be synthesized by further elongation of the peptide chain via continued step- wise coupling of the remaining amino acids.
  • the coupling of the first and second component pieces provides a combined first- second intermediate.
  • Three different combined first-second intermediate species may be formed by coupling the first component piece I with second component pieces 2a, 2b or 2c.
  • the coupling products, identified as l-2a. l-2b. and l-2c. are shown below.
  • P is BOC and P' is FMOC.
  • the coupling of the first and second component pieces may be accomplished by a silicon mediated acid fluoride coupling.
  • solid phase immobilized I is converted to the corresponding N-trimethylsilyl derivative Qa below) by treatment with 5 equivalents of bis(trimethylsilyl)acetamide.
  • the general silicon mediated acid fluoride peptide coupling procedure described above may be utilized to couple N-protected amino acid fluorides (such as 2a or 2b) with N-silyl peptides (such as Is).
  • N-protected amino acid fluorides are coupled to carboxy protected N-silyl amino acids.
  • the silicon mediated acid fluoride coupling method represents an advancement over traditional amide forming reactions which employ coupling agents such as carbodiimides or mixed anhydride reagents. These reagents activate the carboxyl group of an amino acid for coupling with the amino group of another amino acid.
  • coupling between the amino terminus and carbonyl group can be effected with HATU.
  • reaction rates for the coupling of amino acids with relatively bulky side chains are significantly less compared with those amino acids having relatively les sterically demanding side chains such as glycine, alanine, and serine in coupling reaction which utilize N-FMOC protected amino acids.
  • Peptide bond formation with secondary amines such as la is also more difficul for steric reasons.
  • the additional amino substitutent significantly increases the steri hinderance of the amine group and diminishes its nucleophilicity (ability to form peptid bond with a carboxy derivative).
  • the diminution of reactivity is manifested in slo reaction rates. This difficulty in peptide coupling is especially true in reactions with N FMOC protected amino acids.
  • the azido group may be directly activated for subsequent couplings.
  • the overall result for either acid fluoride reagent is peptide bond formation.
  • the azido acid fluoride reagent does not suffer from the problems of steric inhibition o peptide bond formation associated with N-FMOC protected amino acids.
  • azido acid fluorides are the reagents of choice for sterically demanding peptide bond formation. These couplings include reactions of amino acids with sterically bulky side chain moieties and amide bond formation with secondary amines.
  • the structures of these acid fluorides is shown below (R represents an amino acid side chain moiety or derivative thereof).
  • the azido acid fluorides may be prepared from their corresponding azido acids, and the azido acids may be readily synthesized from the corresponding amino acids, by standard methods as disclosed above.
  • azido acids may be directly activated for peptide coupling with a subsequent amino acid.
  • Treatment of the azido peptide with tnphenyl phosphine generates a phosphine imine which, upon reaction with an amino acid or a second or third component piece of the present invention yields a peptide bond and the corresponding chain lengthened peptide.
  • R is an amino acid side chain moiety:
  • the azido acid fluoride peptide coupling method described above has utility in peptide coupling in general and, more specifically, in the practice of the present invention. This method is further illustrated for coupling of the modular component pieces of the present invention in sections C, D, and E below.
  • the coupling of the first modular component and third modular componen pieces provides a combined first-third intermediate.
  • Six different combined first-thir intermediate species may be formed as result of the coupling of first component piece with either third component piece 3(al). 3(a2). 3(a3). 3(a4). 3b, or 3c.
  • the couplin products, identified as l-3(al). l-3(a2). l-3(a3). l-3(a4). l-3(b). and l-3(c). are shown below:
  • P is a protective group suitable for use in peptide synthesis
  • X is a linker as described in Example 1
  • R 1 , R 2 , R 3 and R 4 represent an amino acid side chain moiety.
  • the coupling of the first and third component pieces is accomplished by the silicon mediated acid fluoride method as described in section A above via N-silyl derivative la.
  • the combined first-third intermediates are precursors for conformationally constrained gamma-turn mimetic synthesis.
  • the coupling of a combined first-second intermediate with a third modular component piece provides a combined first-second-third intermediate.
  • Eighteen different combined first-second-third intermediate species may be formed as result of coupling each of the three first-second intermediates l-2(a). l-2(b). or l-2(c) with each of the six third component pieces 3(a)-3(c).
  • the products of coupling l-2(a) with 3(a)- 3(c). a representative set of first-second-third intermediate coupling products, identified as l-2(a)-3(al).
  • l-2(a)-3(b). and l-2(a)-3(c). are shown below:
  • P is a protective group suitable for use in peptid synthesis
  • X is a linker as described in Example 1
  • Z is either hydrogen or methyl, and represents an amino acid side chain moiety.
  • the coupling of a combined first second intermediate with a third component piece may be accomplished by traditiona peptide coupling techniques such as those performed on automated peptide synthesizers. Briefly, the steps include N-deprotection of the combined first-second intermediate, addition and carboxyl group activation of the third component piece which results in peptide bond formation and coupling.
  • the combined first-second-third intermediates are precursors required fo conformationally constrained beta-turn mimetic synthesis.
  • D Representative Coupling of a Combined First-Second Component Intermediate with a Second Component Piece
  • the coupling of a combined first-second intermediate with a second modular component piece provides a combined first-second-second intermediate.
  • Nine different combined ⁇ rst-second-second intermediate species may be formed as result of the coupling each of the three first-second intermediates l-2(a). 1 -2(b). or l-2(c) with each of the three second component pieces 2(a)-2(c).
  • the products of coupling l-2(a) with 2(a)-2(c). a representative set of first-second-second intermediate coupling products, identified as l-2(a)-2(a). l-2(a)-2(b). and l-2(a)-2(c). are shown below:
  • P is a protective group suitable for use in peptide synthesis
  • X is a linker as described in Example 1
  • R represents an amino acid side chain moiety.
  • the coupling of a combined first-second-second intermediate with a thir modular component piece provides a combined first-second-second-third intermediate.
  • Forty-five different combined first-second-second-third intermediate species may b formed as result of the coupling each of the nine first-second-second intermediates 1 2(a)-2(a). l-2(a)-2(b). l-2(a)-2(c). l-2(b)-2(a). l-2(b)-2(b). l-2(b)-2(c), l-2(c)-2(a), _ 2(c)-2(b). and l-2(c)-2(c) with each of the five third component pieces 3(a)-3(c).
  • the products of coupling l-2(a)-2(a) with 3(al). a representative species of first-second- second-third intermediate coupling products, identified as l-2(a)-2(a)-3(al). is shown below:
  • P is a protective group suitable for use in peptide synthesis
  • X is a linker as described in Example 1
  • R represents an amino acid side chain moiety.
  • the coupling of a combined first-second-second intermediate with a third component piece may be accomplished by the peptide coupling techniques described in C above.
  • the combined first-second-second-third intermediates are precursors required for conformationally constrained beta-bulge mimetic synthesis.
  • the cyclization of the first and third modular component pieces through covalent coupling of linking group X of the first component piece with the carbonyl carbon of the azetidinone group of the third component piece yields the conformationally constrained reverse-turn mimetics of the present invention.
  • the presence of component pieces between the first and third component pieces determines the nature of the conformationally constrained reverse-tum mimetic (i.e., beta-turn, gamma-turn or beta- bulge mimetic).
  • Cyclization of the first component piece to the third component piece involves removal of protecting group P from linking group X of the first component piece.
  • P is an amino protective group, typically a BOC group. Therefore, treatment of the combined intermediate with TFA in CH 2 C1 2 and subsequent neutralization with DIPEA removes the protecting group and provides linking group X, which bears a nucleophilic nitrogen.
  • the nucleophilic nitrogen is either a hydrazine, Example 1A(1), or an amine, Example lA(2)(a-d).
  • the nucleophilic hydrazine or amine of the first component piece results in facile cyclization to the hydrazide or amide, respectively.
  • the ease of cyclization is due to the proximity and the electrophilic nature of the azetidinone carbonyl of the third component piece.
  • A. Representative Conformationally Constrained Beta-Turn Cyclization of a Combined First-Second-Third Modular Component N-deprotection and cyclization of the first-second-third combined intermediate provides the beta-turn mimetic.
  • the combined intermediate may be any one of those described above in Example 2C.
  • aqueous acid treatment of l-2(a)-3(al). for a species where X — -NH- results in cyclization to the conformationally constrained beta-turn mimetic shown below: l-2(a)-3(al)
  • the cyclization depicted above is representative for all beta-turn mimetic cyclizations o the present invention.
  • Cyclization of a Combined First-Second-Second-Third Modular Component N-deprotection and cyclization of a first-second-second-third combined intermediate provides the beta-bulge mimetic.
  • the combined intermediate may be any one of those described above in Example 2E.
  • TFA/CH 2 C1 2 treatment and neutralization of l-2(a)-2(a)-3(al). for a species where X -NH-, results in cyclization to the conformationally constrained beta-bulge mimetic shown below.
  • cyclization depicted above is representative for all beta-bulge mimetic cyclizations of the present invention.
  • the sequence of a linear peptide having known biological activity is obtained.
  • Such a sequences may be of a naturally occurring peptide, a sequence that was identified from a linear peptide library (e.g., synthetic or phage display), or a combination of epitopes that are part of a bioactive region of a protein.
  • the linear peptide is beta-endorphin having the following sequence:
  • H-YGGFM TSEKS QTPLV TLFRN AIIKN AYKKG E-OH The N-terminal sequence of the above peptide ⁇ i.e., YGGFM(L)) is recognized by th anti-beta-endorphin antibody, 3E7 (Boehringer Mannheim) (Lam et al., Nature 354:82- 84, 1991) (incorporated herein by reference).
  • a mimetic library is constructed around the N-terminal, pentapeptide sequence to determine its bound ⁇ i.e., bioactive) conformation as follows: Beta-Turn Mimetics:
  • the first step involves coupling commercially available BOC- Gly-PAM resin to the first two amino acids (i.e., K and L) by DIC, HOBT (i.e., carbodumide coupling) to yield FMOC-LKG-PAM.
  • DIC i.e., HOBT
  • FMOC-LKG-PAM FMOC-LKG-PAM.
  • the next step is reductive amination on the resin to complete the synthesis of the linker, X.
  • the amino acid hydrazide is presynthesized (i.e., the first component piece). Coupling of the second component piece to the hindered secondary amine is effected using HATU (4x). Removal of the FMOC group and coupling to the beta-lactam (i.e., the third component piece) is the same as outlined above in Example 2, and cyclizing the ring with TFA is accomplished by the methods disclosed in Example 3. A further amino acid may be added using HATU, with additional residues added via carbodumide coupling. Cleavage of the reverse-turn mimetics from the resin is effected by aminolysis (NH 3 in isopropanol).
  • the library members are then assayed in a standard ELISA format. Briefly, Costar ELISA strips (2588) are coated with 1 ⁇ g/ml of beta-endorphin (Novabiochem) of carbonate buffer pH 8.6 at 50 ⁇ g well for 1 hour at room temperature, and then washed three times with PBS and 0.5% Tween 20. The wells are filled (about 350 ⁇ l) with blocking buffer (PBS, 1% BSA, and 0.05% Tween 20) and incubated at room temperature for 2 hours and washed three times.
  • beta-endorphin Novabiochem
  • Anti-beta-endorphin antibody (3E7) is diluted to 150 ng/ml in blocking buffer, and the library members are incubated with 3E7 at varying concentration for 30 minutes at room temperature. Then 100 ⁇ l of each mixture is applied to the wells and incubated 30 minutes to 1 hour at room temperature. The linear peptide YGGFLKG is tested similarly as a positive control. After 1 hour, the wells are washed three times and then incubated with Goat-anti-Mouse (Sigma) HRP conjugated antibody at 1:1000 dilution in blocking buffer (100 ⁇ l well) and incubated for 30 minutes to 1 hour at room temperature and washed three times.
  • Goat-anti-Mouse Sigma
  • ABTS (Sigma) is dissolved at 1 ⁇ g/ml in 0JM citrate buffer (pH 4.0) to which is added 10 ⁇ l of 30% H2O2 per ml of solution. 100 ⁇ l of ABTS solution is added per well, incubated at room temperature for 30 minutes, and the optical density is read at 415 nM.
  • the most inhibitory reverse-turn mimetic is indicated by the well having the lowest optical density.
  • the above procedure is then repeated to yield a library containing reverse-turn mimetics having the same template, but having differing amino acid side chain moieties to determine the most biologically active.
  • the side chains of the template are optimized by randomizing the amino acid residues, particular the residues of the ring. Further modification may also be made, such as modifying the amino terminus by, for example, acylation, or by utilizing a mixture of D and L configurations, including an all D configuration.
  • Example 5 Synthesis of a Representative Library Containing Conformationally Constrained Reverse-Turns which Mimetic IL-8 and Identification of a Bioactive Mimetic Therefrom
  • IL-8 is a member of the chemokine superfamily, and has been implicated i inflammation, angiogenesis and neutrophil chemotaxis. Based on structural (Baldwin e al., Proc. Natl. Acad Sci. 88:502-505, 1991) and mutational analysis (Clark-Lewis e al., J. Biol. Chem. 269:16075-16081, 1994) the region of IL-8 involved in binding to its receptor is believed to encompass both the N-terminal residues 4-10 (ELRCQCI) an the loop containing Cys-34 (GPHC). In other words, the IL-8 binding region is believed to involve a linear peptide sequence closely associated with, in three-dimensional space, a reverse-turn structure. To mimic this binding region, a reverse-turn of the present invention is joined to a linear peptide as represented by the following:
  • linear peptide (or mimetic thereof) is covalently joined to one end of a reverse turn mimetic of this invention.
  • a library containing the following structures are synthesized:
  • a library of the above mimetics is constructed in the manner disclosed above in Examples 1-4, with the exception of the linear peptide joined to the carbonyl terminus of the reverse-turn.
  • the peptide IAQ is constructed on PAM resin to yield PAM- IAQ-FMOC.
  • a DDE ( ⁇ -amino FMOC) lysine residue (Bycroft et al., J. Amer. Chem. Soc. 116:7415-7416, 1994) is then coupled thereto.
  • the FMOC group is removed with diethylamine and the synthesis of the reverse-turn proceeds as disclosed by the previous examples.
  • the DDE group is removed with 2% N2H4 at room temperature, and the KLE residues are individually added using carbodumide coupling. Cleavage from the resin is effected as described above.
  • the resulting library is screened by determination of the inhibition of IL-8 included elastase release from human neutrophils which have been pretreated with cytochalasin B.
  • Such an assay is disclosed in Peveri et al., J. Exp. Med 167:1547-1557, 1988 (incorporated herein by reference).
  • the library may also be screened by other procedures, including the assay disclosed in Graminski and Lerner, Biotechnology 12:1008-1011, 1994 (incorporated herein by reference).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Bibliothèques de substances mimétiques de retournement astreintes à une conformation et procédés de construction desdites bibliothèques. Lesdites substances mimétiques de retournement incluent des substances mimétiques à virage bêta, à virage gamma et à renflement bêta qui miment la conformation biologiquement active d'un peptide linéaire. Dans un mode de réalisation préféré, une bibliothèque matrice est construite sur la base de la séquence d'acides aminés du peptide linéaire et contient une pluralité de substances mimétiques à virage bêta, à virage gamma et à renflement bêta de tailles annulaires différentes. La bibliothèque matrice est ensuite criblée dans une analyse adaptée pour identifier un élément de bibliothèque matrice biologiquement actif. Une bibliothèque optimisée est ensuite construite sur la base de la structure de l'élément de matrice biologiquement actif et comprend des substitutions de la séquence d'acides aminés dudit élément. Ladite bibliothèque optimisée est alors criblée de la même manière pour identifier une substance mimétique de retournement biologiquement active. Des procédés concernant l'identification d'éléments de bibliothèque qui entrent en interaction avec des cibles biologiques appropriées et l'utilisation desdits éléments en tant qu'agents diagnostiques, prophylactiques et/ou thérapeutiques sont également décrits.
PCT/US1996/000786 1995-01-20 1996-01-19 Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes WO1996022304A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8522413A JPH10512570A (ja) 1995-01-20 1996-01-19 コンホメーション的に制限された逆ターンライブラリおよびそれらに関連する方法
AU47619/96A AU4761996A (en) 1995-01-20 1996-01-19 Conformationally constrained reverse-turn library and methods relating thereto
EP96903585A EP0804460A1 (fr) 1995-01-20 1996-01-19 Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37590495A 1995-01-20 1995-01-20
US08/375,904 1995-01-20

Publications (1)

Publication Number Publication Date
WO1996022304A1 true WO1996022304A1 (fr) 1996-07-25

Family

ID=23482840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000786 WO1996022304A1 (fr) 1995-01-20 1996-01-19 Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes

Country Status (5)

Country Link
EP (1) EP0804460A1 (fr)
JP (1) JPH10512570A (fr)
AU (1) AU4761996A (fr)
CA (1) CA2210349A1 (fr)
WO (1) WO1996022304A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048913A1 (fr) * 1998-03-24 1999-09-30 The University Of Queensland Mimetiques d'enroulement peptidique
EP1015479A1 (fr) * 1997-04-11 2000-07-05 Eli Lilly And Company Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
WO2001000210A1 (fr) * 1999-06-25 2001-01-04 Molecumetics Ltd. Mimetiques de coudes inverses et methodes associees
WO2001025257A2 (fr) * 1999-10-04 2001-04-12 Neokimia, Inc. Synthese combinatoire de bibliotheques de composes macrocycliques utilisables dans la recherche medicamenteuse
AU742747B2 (en) * 1998-03-24 2002-01-10 Mimetica Pty Ltd Peptide turn mimetics
WO2005012332A1 (fr) * 2003-07-31 2005-02-10 Tranzyme Pharma Composes macrocycliques definis spatialement incorporant des substituts de liaison peptidique
WO2005012331A1 (fr) * 2003-07-31 2005-02-10 Tranzyme Pharma Composes macrocycliques definis spatialement utiles pour la decouverte de medicaments
US7345040B2 (en) 2002-10-17 2008-03-18 Myriad Genetics, Inc. Reverse-turn mimetics and compositions and methods relating thereto
US8008291B2 (en) 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009040696A (ja) * 2007-08-07 2009-02-26 Kikkoman Corp 新規アンジオテンシン変換酵素阻害ペプチド

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013878A2 (fr) * 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Produits mimetiques de conformation restreinte de tours beta et bombements beta, et peptides les contenant
WO1994003494A1 (fr) * 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Agents mimetiques restreints dans leur conformation de girations inverses, et peptides les contenant
WO1994008051A1 (fr) * 1992-10-01 1994-04-14 The Trustees Of Columbia University In The City Of New York Banques chimiques combinatoires complexes codees avec des etiquettes
WO1994028028A1 (fr) * 1993-05-27 1994-12-08 Selectide Corporation Banques en phase solide codees a segregation topoligique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013878A2 (fr) * 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Produits mimetiques de conformation restreinte de tours beta et bombements beta, et peptides les contenant
WO1994003494A1 (fr) * 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Agents mimetiques restreints dans leur conformation de girations inverses, et peptides les contenant
WO1994008051A1 (fr) * 1992-10-01 1994-04-14 The Trustees Of Columbia University In The City Of New York Banques chimiques combinatoires complexes codees avec des etiquettes
WO1994028028A1 (fr) * 1993-05-27 1994-12-08 Selectide Corporation Banques en phase solide codees a segregation topoligique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A A VIRGILIO & J A ELLMANN: "Simultaneous solid-phase synthesis of beta-turn mimetics incorporating side-chain functionality", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 116, no. 25, 14 January 1994 (1994-01-14), DC US, pages 11580 - 11581, XP002004648 *
DATABASE CAPLUS [online] CHALMERS, DAVID K.: "PRO-D-NME-AMINO ACID AND D-PRO-NME-AMINO ACID: SIMPLE, EFFICIENT REVERSE-TURN CONSTRAINTS", XP002004649, accession no. STN Database accession no. 1995:592240 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, no. 22, 1995, pages 5927 - 5937 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413963B2 (en) 1995-10-27 2002-07-02 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US7598253B2 (en) 1995-10-27 2009-10-06 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
US6548500B2 (en) 1995-10-27 2003-04-15 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
EP1015479A1 (fr) * 1997-04-11 2000-07-05 Eli Lilly And Company Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
EP1015479A4 (fr) * 1997-04-11 2002-07-24 Lilly Co Eli Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
JP4801257B2 (ja) * 1998-03-24 2011-10-26 ミメーティカ プロプライエタリー リミテッド ペプチドターン模倣構造体
JP2002507624A (ja) * 1998-03-24 2002-03-12 ザ ユニバーシティ オブ クイーンズランド ペプチドターン模倣構造体
AU742747B2 (en) * 1998-03-24 2002-01-10 Mimetica Pty Ltd Peptide turn mimetics
WO1999048913A1 (fr) * 1998-03-24 1999-09-30 The University Of Queensland Mimetiques d'enroulement peptidique
WO2001000210A1 (fr) * 1999-06-25 2001-01-04 Molecumetics Ltd. Mimetiques de coudes inverses et methodes associees
US9018419B2 (en) 1999-10-04 2015-04-28 Ocera Therapeutics, Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US8008440B2 (en) 1999-10-04 2011-08-30 Tranzyme Pharma Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
WO2001025257A2 (fr) * 1999-10-04 2001-04-12 Neokimia, Inc. Synthese combinatoire de bibliotheques de composes macrocycliques utilisables dans la recherche medicamenteuse
WO2001025257A3 (fr) * 1999-10-04 2001-12-06 Neokimia Inc Synthese combinatoire de bibliotheques de composes macrocycliques utilisables dans la recherche medicamenteuse
US8188216B2 (en) 1999-10-04 2012-05-29 Tranzyme Pharma Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US9409945B2 (en) 1999-10-04 2016-08-09 Ocera Therapeutics, Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US7345040B2 (en) 2002-10-17 2008-03-18 Myriad Genetics, Inc. Reverse-turn mimetics and compositions and methods relating thereto
WO2005012332A1 (fr) * 2003-07-31 2005-02-10 Tranzyme Pharma Composes macrocycliques definis spatialement incorporant des substituts de liaison peptidique
WO2005012331A1 (fr) * 2003-07-31 2005-02-10 Tranzyme Pharma Composes macrocycliques definis spatialement utiles pour la decouverte de medicaments
US7452862B2 (en) 2003-07-31 2008-11-18 Tranzyme Pharma, Inc. Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
US8022252B2 (en) 2003-07-31 2011-09-20 Tranzyme Pharma Inc. Spatially-defined macrocyclic compounds useful for drug discovery
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US8008291B2 (en) 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US9340517B2 (en) 2008-02-29 2016-05-17 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists

Also Published As

Publication number Publication date
JPH10512570A (ja) 1998-12-02
CA2210349A1 (fr) 1996-07-25
EP0804460A1 (fr) 1997-11-05
AU4761996A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
US5811387A (en) Peptoid mixtures
JP3469579B2 (ja) イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー
Maeji et al. Multi-pin peptide synthesis strategy for T cell determinant analysis
AU743777B2 (en) Reverse-turn mimetics and methods relating thereto
AU683184B2 (en) Libraries of modified peptides with protease resistance, derivatives thereof and methods of producing and screening such
Souers et al. β-Turn mimetic library synthesis: scaffolds and applications
US5641862A (en) General method for producing and selecting peptides with specific properties
CA1340067C (fr) Methode generale pour la production et la selection de peptides aux proprietes specifique
JP2679786B2 (ja) 非ペプチド結合を有するペプチド合成方法
WO1996022304A1 (fr) Bibliotheque de substances mimetiques de retournement astreintes a une conformation et procedes associes
US20030027982A1 (en) Method for inverse solid phase synthesis of peptides
US5639852A (en) Immunostimulatory agents
Gennari et al. Solid‐Phase Synthesis of Peptides Containing Reverse‐Turn Mimetic Bicyclic Lactams
WO1999031124A1 (fr) Echafaudages a base d'acide cholique pour la presentation moleculaire multidimensionnelle de peptides
CA2579631C (fr) Methode et systeme fournissant un controle de parite a faible densite et a courte longueur de blocs
Xiong et al. Stereoselective synthesis of individual isomers of Leu-enkephalin analogues containing substituted β-turn bicyclic dipeptide mimetics
CA2165780C (fr) Liants clivables de facon selective, a base de liaisons de type ester iminodiacetate
Lescrinier et al. Amino acids derived from ornithine
Helms et al. Proteolytic excision and in situ cyclization of a bioactive loop from an REI‐VL presentation scaffold
AU2286401A (en) Peptide beta-turn mimetic compounds and processes for making them
HU208158B (en) Process for the synthesis of 1h-rh analogs by temporary protection
Ostresh et al. Clemencia Pinilla, Jon A ppel, Colette Dooley, Sylvie Blondelle, Jutta Eichler, Barbara Dorner

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2210349

Country of ref document: CA

Ref country code: CA

Ref document number: 2210349

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996903585

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 522413

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996903585

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996903585

Country of ref document: EP